Search for a trial

A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma, or Triple-Negative Breast Cancer (TNBC) (CATALYST)

Primary ObjectivesPhase 1bConfirm the recommended CyPep-1 dose 20 mg every two weeks (Q2W) when administered by intratumoral (IT) injection in combination with pembrolizumab Phase 2aAssess the anti-tumor activity of CyPep-1 administered by IT…

Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors

This study has been transitioned to CTIS with ID 2024-514461-19-00 check the CTIS register for the current data. Phase 1 - Primary Objective• To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single-agent MCLA-…

An open label, multicentre, positron emission tomography (PET) imaging study using Zirconium-89 to investigate the biodistribution and tumor uptake of a PD-L1x4-1BB bispecific antibody (S095012) in patients with advanced solid tumors

Objectives of Part A, B and C are the following:­ Part A: determination of the optimal mass dose of S095012 to inject with 89Zr-S095012 and optimal time point for PET scans for appropriate visualisation of 89Zr-S095012 through PET imaging.­ Part B…

A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients with Advanced Solid Tumors.

Part BPrimary:• To determine the anti-tumor activity of NM21 1480 according to RECIST 1.1• To assess the safety and tolerability of NM21 1480 in patients with selected advanced cancers treated at or around the recommended Phase 2 dose (RP2D)• To…

PHARMACOKINETICS OF APREPITANT, DEXAMETHASONE AND THEIR INTERACTION IN PATIENTS WITH CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

Primary objective:The primary objective of this study is to define the differences in the interaction between oral dexamethasone and aprepitant and the interaction between iv dexamethasone and aprepitant.Secondary objective:The secondary objective…

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Primary ObjectiveTo evaluate the antitumor activity of tucatinib given in combination with trastuzumab in subjects with previously treated, locally-advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2) overexpressing/…

A phase 1, first-in-human, multicenter, open-label, dose-escalation study to characterize the safety and tolerability of MP0317 in patients with relapsed/refractory advanced solid tumors

Primary Objectives:• To determine the Recommended Dose of Expanion or the MTD for MP0317 as monotherapy in patients with advanced solid tumors (dose-escalation part only)• To characterize the safety and tolerability of MP0317 as monotherapy in…

An open label Phase I PET imaging study to investigate the bio-distribution and tumor uptake of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in patients with head and neck squamous cell carcinoma, non-small cell lung cancer or melanoma who are treated with ezabenlimab

This study has been transitioned to CTIS with ID 2024-514034-20-00 check the CTIS register for the current data. The primary objective is to estimate the average relative change from baseline in tumoruptake of [89Zr]Zr-BI 765063 (arm A) or [89Zr]Zr-…

Phase II non-randomized study on proton radiotherapy of thymic malignancies

To investigate te efficacy and the toxicity of protone radiation of thymomas and thymic carcinomas.

A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with head and neck squamous cell carcinoma (HNSCC) (Pegasus Head and Neck 204)

Primary:•To determine the antitumor activity of SAR444245 in combination with other anti-cancer therapies in patients with HNSCCSecondary:•To assess the safety profile of SAR444245 when combined with other anti-cancer therapies• To assess other…

A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors

This study has been transitioned to CTIS with ID 2023-505284-36-00 check the CTIS register for the current data. Objective 1: To compare MK-7684A to pembrolizumab alone with respect to ORR in participants with cervical cancer whose tumors express PD…

Pituitary Gland Stimulation for pain relief

To establish if targeted pituitary stimulation results in pain relief in cancer patients with opioid refractive pain or intolerance to opioids and patients with severe central neuropathic pain.

UltraSound-guided resection of tongue cancer - Multicenter

A relatively new method to determine margin distance is intraoral resection with a small Ultrasound (US)-probe. US is already used to determine tumor-thickness in tongue cancer preoperatively, because of its high predictive value. Four previous…

OPEN LABEL PHASE 2 BASKET TRIAL WITH ATEZOLIZUMAB AND TIRAGOLUMAB IN SOLID TUMORS: TIRACAN

This study has been transitioned to CTIS with ID 2024-512616-21-00 check the CTIS register for the current data. The main objective of the trial is to determine the pathological response rate in cohort 1 and the radiological response rates in cohort…

First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors

This study has been transitioned to CTIS with ID 2024-512639-58-00 check the CTIS register for the current data. ____________________PRIMARY OBJECTIVESFor Parts 1 and 2: To assess the safety and tolerability of BNT142 at all dose …

Prospective sampling in intravenously treated oncology patients: Monoclonal AntiBodies

To map the pharmacokinetics of monoclonal antibodies.

A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies

Primary: Phase I: - To characterize the safety and tolerability of MBG453 as a single agent and in combination with PDR001 and to identify recommended doses for future studies. To further investigate the safety and tolerability of different doses of…

Assessing Frequency of HLA-Genotype and Tumor Antigen Expression in Subjects with Relapsed/Refractory, Advanced-Stage Solid Tumors that may Qualify for Novel T Cell Receptor Based
Therapies

The primary objective of this study is to assess the frequency of human leukocyte antigen (HLA)-A*02:01genotype and tumoral expression of melanoma-associated antigen 1 (MAGE-A1) in subjects with relapsed/refractory, advanced-stage solid tumors that…

A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Primary Objectives1) To compare the Progression Free Survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR) in first line recurrent / metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) subjects, treated…

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)

This study has been transitioned to CTIS with ID 2022-501253-37-00 check the CTIS register for the current data. The primary efficacy objective of this trial is to evaluate the anti-tumor activity of pembrolizumab in subjects with any of a *basket*…